Mergers as Strategic Architecture: Rethinking How to Evaluate the AstraZeneca–BMS Rumors

This is part two of a multipart series on the implications of the rumored merger discussions between AstraZeneca and Bristol Myers Squibb (BMS). Click here to read part one.

The rumored AstraZeneca–Bristol Myers Squibb merger discussions may ultimately be remembered less for their unprecedented scale than for what they reveal about where pharmaceutical competition is heading.

Part one of this series examined the financial signals behind each company's strategic position with AstraZeneca's sustained growth trajectory, BMS’ looming patent cycle, and the asymmetry that makes this something other than a traditional consolidation play.

But financial analysis only goes so far. The deeper question is whether the rules of pharmaceutical competition are changing fast enough that today's strongest companies need to build capabilities that don't yet show up in any income statement.

BMS: Managing the Transition to the Next Growth Cycle

BMS remains one of the pharmaceutical industry's strongest companies, as its commercial organization is among the most respected globally. The company continues to generate substantial operating cash flow, maintains leading positions in oncology, hematology, immunology, and cardiovascular disease, and has consistently demonstrated the ability to develop and commercialize innovative medicines. Yet financial strength alone does not eliminate strategic pressure.

Like many mature pharmaceutical companies, BMS faces a well-understood patent cycle. Products that have generated extraordinary shareholder value over the past decade will inevitably encounter biosimilar or generic competition.

The challenge is not simply replacing individual products; it is replacing an entire generation of revenue. The FactSet growth analysis reflects this transition.

While Bristol Myers continues to generate strong margins and robust free cash flow, investor expectations for long-term growth remain more restrained than those for AstraZeneca. The market is effectively asking one question:

What comes after today's blockbusters?

This is a familiar challenge within the pharmaceutical industry. Historically, companies have responded through internal research, licensing agreements, targeted acquisitions, or transformational mergers. Viewed from this perspective, AstraZeneca represents more than an acquisition target; it represents accelerated portfolio renewal.

The company's strength in oncology, rare diseases, cardiovascular, renal and metabolism, respiratory medicine, and biologics immediately broadens BMS’ future growth profile while reducing dependence on a smaller number of mature franchises.

Therefore, for BMS, the strategic logic is largely financial—diversify future revenue, reduce patent concentration risk, and strengthen long-term earnings growth. Those objectives are rational and consistent with previous large pharmaceutical acquisitions.

AstraZeneca: Building Strategic Advantage Before It Becomes Necessary

The strategic rationale for AstraZeneca is considerably more intriguing. Unlike BMS, AstraZeneca does not appear to require a transformational acquisition to sustain near-term growth. Public financial information and the FactSet analysis indicate that the company has delivered one of the strongest growth trajectories among global pharmaceutical companies.

Revenue has expanded substantially over the past several years. The company's geographic footprint is also considerably more diversified than many of its global peers, reducing dependence on any single healthcare market.

From a purely financial perspective, AstraZeneca appears well positioned to continue executing its existing strategy, which raises a more interesting strategic question.

Why undertake one of the largest and most complex mergers in pharmaceutical history when your current strategy is already working?

The answer may lie in recognizing that the pharmaceutical industry is changing faster than traditional financial metrics capture. Management teams often make strategic decisions years before those decisions become obvious in financial results.

The companies that ultimately define an industry's future rarely wait until competitive pressures become unavoidable. They invest before the need becomes urgent—and this appears consistent with AstraZeneca's broader strategic history.

The Alexion acquisition was not undertaken because AstraZeneca lacked growth, it strengthened the company's position in rare diseases and diversified its innovation platform. Similarly, investments in antibody-drug conjugates, radiopharmaceuticals, advanced biologics, and precision medicine suggest a management philosophy focused on anticipating future sources of competitive advantage rather than simply optimizing current financial performance.

If that philosophy extends to the reported BMS discussions, the transaction becomes easier to understand. Rather than solving today's financial problem, AstraZeneca may be preparing for tomorrow's competitive environment.

Different Assets, Different Contributions

The financial evidence suggests that each organization contributes a different strategic asset to the proposed combination. AstraZeneca contributes sustained revenue growth, broad therapeutic diversification, geographic balance, and one of the industry's strongest innovation trajectories.

BMS contributes exceptional cash generation, deep oncology expertise, one of the strongest commercial infrastructures in the United States, extensive payer relationships, and decades of clinical development experience. These assets are complementary rather than redundant and that distinction matters.

Many mergers seek efficiency through eliminating overlap, but this rumored transaction appears to seek value through combining complementary capabilities. The objective is not simply becoming larger, it is to become more capable.

Looking Beyond Financial Synergies

Traditional merger models evaluate success through measurable financial outcomes, including revenue synergies, cost reductions, earnings accretion, and operating margin improvement. Those measures remain important; however, they are unlikely to capture the full strategic value of a transaction such as this.

There are more relevant questions as to whether the combined organization would be better positioned to compete under future industry conditions:

• Can it accelerate AI-enabled drug discovery?
• Can it integrate larger clinical datasets?
• Can it strengthen manufacturing resilience?
• Can it improve global market access?
• Can it better withstand geopolitical disruption?
• Can it build capabilities that neither company could reasonably develop independently?

These questions shift merger analysis from financial engineering to strategic architecture. That shift is precisely what distinguishes the pharmaceutical industry entering the next decade from the one that existed over the past thirty years.

The Real Strategic Asymmetry

Perhaps the most important insight emerging from the FactSet analysis is that the proposed transaction is asymmetric in ways that traditional merger models do not fully capture. For BMS, the strategic imperative is clear: secure future growth. For AstraZeneca, the strategic imperative appears broader: secure future leadership.

Those are fundamentally different objectives, as one responds to financial transition and the other anticipates industry transformation. Recognizing that distinction changes how the proposed merger should be evaluated.

Rather than asking whether AstraZeneca should acquire BMS, executives should ask a more important question: What capabilities will define pharmaceutical leadership in 2035 and does this transaction accelerate their development?

The New Basis of Competitive Advantage: From Products to Integrated Capabilities

If the financial evidence explains why BMS might view AstraZeneca as an attractive merger partner, it does not fully explain why AstraZeneca would contemplate assuming the complexity, integration risk, and regulatory scrutiny associated with what could become the largest pharmaceutical transaction in history.

The answer may lie in recognizing that pharmaceutical competition itself is undergoing a structural transformation. For most of the modern pharmaceutical era, competitive advantage rested on three foundations: scientific innovation, patent protection, and commercial execution.

Companies that consistently discovered breakthrough therapies, secured strong intellectual property, and built global sales organizations generated superior shareholder returns. Scale certainly mattered, but it primarily served to improve research productivity, expand commercial reach, and reduce operating costs.

Today, those traditional sources of advantage remain essential, but they are no longer sufficient. The pharmaceutical industry is entering a period in which competitive leadership will increasingly depend on an organization's ability to integrate capabilities that historically operated as separate business functions.

AI, manufacturing resilience, regulatory intelligence, market access, digital health, real-world evidence, and global supply chain management are no longer supporting activities, they are becoming strategic differentiators. The reported AstraZeneca–BMS discussions should be viewed not simply as an effort to combine two product portfolios but as an attempt to strengthen the capabilities required to compete in this emerging environment.

AI is Redefining Scale

Perhaps the most significant change reshaping pharmaceutical strategy is the rapid integration of AI across the entire value chain. Initially, AI was viewed primarily as a tool for accelerating target identification and drug discovery, but today, its applications extend much further.

Machine learning supports clinical trial design, patient recruitment, biomarker identification, manufacturing optimization, pharmacovigilance, demand forecasting, pricing analytics, and commercial engagement. Increasingly, every stage of pharmaceutical development generates data that improve subsequent decisions.

This evolution changes the strategic value of scale. Historically, larger organizations achieved economies of scale through purchasing power, manufacturing efficiency, and broader commercialization.

In an AI-enabled industry, scale also creates economies of intelligence. Larger organizations generate more clinical data, manufacturing data, genomic data, real-world evidence, payer interactions, and commercial insights.

Each dataset strengthens predictive models, improves decision-making, and enhances future innovation. The competitive advantage lies not simply in being larger, but in creating a continuously learning enterprise.

A combined AstraZeneca–BMS organization would possess one of the industry's richest collections of scientific, clinical, manufacturing, regulatory, and commercial data. Properly integrated, these assets could accelerate innovation in ways that extend well beyond traditional merger synergies.

Manufacturing Has Become Strategic Infrastructure

The COVID-19 pandemic permanently changed how pharmaceutical executives think about manufacturing. Before 2020, manufacturing discussions focused primarily on productivity, quality, cost, and inventory management. Today, manufacturing is increasingly viewed through a different lens: resilience.

Governments now evaluate pharmaceutical companies not only by their ability to discover innovative medicines but also by their ability to manufacture and deliver them reliably during periods of disruption. Industrial policies in the United States, Europe, and Asia increasingly encourage domestic production of essential medicines, while geopolitical tensions continue to reshape sourcing decisions, technology transfers, and investment priorities.

These developments have elevated manufacturing from an operational capability to a strategic asset. The significance of this shift becomes evident when considering the capabilities that AstraZeneca and BMS would bring together.

Both companies have invested heavily in biologics manufacturing, global production networks, quality systems, and advanced manufacturing technologies. A combined organization would possess greater geographic flexibility, broader production capacity, and increased ability to respond to regional disruptions or regulatory changes.

Unlike traditional merger synergies, these advantages are not primarily about reducing cost, they are about increasing resilience.

Supply Chains Now Influence Competitive Position

The pharmaceutical supply chain has also undergone a strategic transformation. Historically, supply-chain management emphasized efficiency, procurement savings, and inventory optimization, whereas currently, executives must balance efficiency with resilience.

Global disruptions over the past several years have demonstrated that pharmaceutical companies cannot assume uninterrupted access to active pharmaceutical ingredients, specialized manufacturing inputs, transportation infrastructure, or critical suppliers. At the same time, governments increasingly expect companies to maintain reliable access to essential medicines even during periods of geopolitical uncertainty.

This broader operating environment reinforces what I have previously described as supply chain immunity—the capability of an organization to anticipate, absorb, recover from, and adapt to disruption while maintaining continuity of patient access and business performance.

Viewed through this perspective, manufacturing networks, supplier diversification, and global logistics are more than just operational considerations, as they have become strategic assets that directly influence corporate competitiveness.

Data Have Become a Strategic Asset

Perhaps the most valuable resource within modern pharmaceutical organizations is no longer physical infrastructure—it is data:

• Every clinical study generates evidence.
• Every manufacturing batch produces operational insights.
• Every regulatory submission contributes institutional knowledge.
• Every payer negotiation improves understanding of healthcare economics.
• Every patient interaction expands real-world evidence.

Historically, many of these data remained fragmented across individual business functions. Increasingly, competitive advantage depends upon integrating them into a unified knowledge platform.

This may represent one of the most compelling strategic arguments supporting large-scale pharmaceutical combinations. The value created is not just additional revenue, it’s organizational intelligence, which becomes increasingly difficult for competitors to replicate.

Competitive Advantage is Becoming Cumulative

The defining characteristic of future pharmaceutical leaders may not be the number of products they sell but may be the number of capabilities they integrate.

• Scientific innovation improves clinical development.
• Clinical development generates richer datasets.
• Better datasets strengthen AI.
• AI accelerates discovery.
• Manufacturing resilience supports global commercialization.
• Commercial success generates additional real-world evidence.

The cycle continuously reinforces itself, representing a fundamentally different model of competition than the blockbuster era. Instead of optimizing individual functions, successful organizations optimize interactions among functions. Competitive advantage becomes cumulative rather than additive.

The Emerging Enterprise

Viewed through this broader lens, the AstraZeneca–BMS discussions appear less like a traditional acquisition and more like an effort to build an enterprise designed for the next phase of pharmaceutical competition.

This does not diminish the importance of financial synergies or pipeline expansion but instead suggests they are only part of the strategic rationale. The more enduring value may lie in creating an organization capable of integrating science, AI, manufacturing, regulatory expertise, commercial excellence, and resilient global operations into a continuously improving system.

That perspective also changes how future mergers should be evaluated. The critical question is no longer simply: "How much value can be extracted from combining two companies?" It becomes: "How much new capability can be created by integrating them?"

Executive Insight

The evidence suggests that pharmaceutical competition is evolving beyond molecules and markets toward integrated enterprise capabilities. Companies that succeed in the coming decade will not simply possess stronger pipelines or larger commercial organizations.

They will build adaptive enterprises capable of learning faster, innovating more effectively, and responding more rapidly to scientific, technological, regulatory, and geopolitical change. If this interpretation is correct, then any AstraZeneca–BMS discussions may ultimately be remembered less as the industry's largest proposed merger than as one of its earliest signals that the rules of pharmaceutical competition had fundamentally changed.

This is part two of a multipart series. Check back with PharmExec tomorrow for part three. Click here to read part one.

About the Author

Dr. Thani Jambulingam is Dirk Warren ’50 Sesquicentennial Faculty Chair in Business and Professor of Pharmaceutical & Healthcare Business at Saint Joseph's University, where he teaches and research in pharmaceutical strategy, healthcare marketing, market access, healthcare supply chains, and AI applications in life sciences. His research focuses on pharmaceutical competitiveness, healthcare innovation, strategic market access, supply-chain resilience, and the evolving role of artificial intelligence in healthcare. He is also the originator of the Supply Chain Immunity Theory.